Clinical study of the effectiveness of Mecitentan and Victoria Burbura 09/01/2015
Clinical study of the effectiveness of Mecitentan and Victoria Burbura.
Christmas is a holiday during which miracles may happen. That's what happened to Victoria, the patient of LCCF of “Sister Dalila”. She is now included in the clinical trial of macitentan, an effective drug to treat pulmonary hypertension. http://en.wikipedia.org/wiki/Macitentan . The program, however, is a placebo controlled. It means that Victoria will receive medication for a short period of time not knowing whether it is only an active substance or placebo. No doubts, she has a good chance to slow down the progression of the disease and to improve quality of life. At the same time, Victoria can not stop pre-treatment (iloprost and sildenafil) as the pressure in the pulmonary artery is still very high. Given this, and placebo-controlled design of clinical studies she will continue to need funds for resuming treatment with adequate doses of medications.
The fact that Victoria has been included in clinical research is undoubtedly positive. We hope that macitentan will soon be registered in Ukraine and will be available to all patients with PH.